Agios Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AGIO)

$55.00 -1.08 (-1.93 %)
(As of 12/14/2017 04:00 PM ET)
Previous Close$55.00
Today's Range$53.80 - $57.22
52-Week Range$39.24 - $72.73
Volume362,248 shs
Average Volume509,415 shs
Market Capitalization$2.73 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.83

About Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals logoAgios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AGIO
CUSIPN/A
Phone617-649-8600

Debt

Debt-to-Equity RatioN/A
Current Ratio6.00%
Quick Ratio6.00%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$69.89 million
Price / Sales38.36
Cash FlowN/A
Price / CashN/A
Book Value$8.53 per share
Price / Book6.45

Profitability

Trailing EPS($6.27)
Net Income$-198,470,000.00
Net Margins-506.39%
Return on Equity-69.64%
Return on Assets-43.12%

Miscellaneous

Employees287
Outstanding Shares48,750,000

Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, beating the consensus estimate of ($1.78) by $0.19. The biopharmaceutical company had revenue of $11.35 million for the quarter, compared to analyst estimates of $10.85 million. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The business's quarterly revenue was up 26.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.63) earnings per share. View Agios Pharmaceuticals' Earnings History.

When will Agios Pharmaceuticals make its next earnings announcement?

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February, 14th 2018. View Earnings Estimates for Agios Pharmaceuticals.

Where is Agios Pharmaceuticals' stock going? Where will Agios Pharmaceuticals' stock price be in 2017?

12 analysts have issued twelve-month target prices for Agios Pharmaceuticals' shares. Their forecasts range from $57.00 to $90.00. On average, they anticipate Agios Pharmaceuticals' share price to reach $75.70 in the next twelve months. View Analyst Ratings for Agios Pharmaceuticals.

What are Wall Street analysts saying about Agios Pharmaceuticals stock?

Here are some recent quotes from research analysts about Agios Pharmaceuticals stock:

  • 1. Cann analysts commented, "Agios announced on December 5, 2017 the appointment of Jacqualyn Fouse, Ph.D. to its board of directors. Dr. Fouse has served as executive chair of Dermavant since July 2017 and was previously chief operating officer of Celgene and member of Celgene’s board of directors." (12/5/2017)
  • 2. Cowen Inc analysts commented, "Agios ended 2016 with $574MM in cash, enough to last through 2018." (2/16/2017)

Who are some of Agios Pharmaceuticals' key competitors?

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the folowing people:

  • David P. Schenkein M.D., President, Chief Executive Officer, Director (Age 59)
  • Andrew Hirsch, Chief Financial Officer (Age 46)
  • Scott Biller Ph.D., Chief Scientific Officer (Age 61)
  • Christopher Bowden M.D., Chief Medical Officer (Age 56)
  • Steven L. Hoerter, Chief Commercial Officer (Age 46)
  • Lewis Clayton Cantley Ph.D., Director (Age 68)
  • Jacqualyn A. Fouse Ph.D., Director (Age 56)
  • David Scadden M.D., Director
  • Paul J. Clancy, Independent Director (Age 55)
  • Ian T. Clark, Independent Director (Age 56)

Who owns Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Capital International Investors (6.44%), Capital Guardian Trust Co. (1.50%), First Trust Advisors LP (1.33%), Alkeon Capital Management LLC (0.94%), Artal Group S.A. (0.92%) and Janus Henderson Group PLC (0.80%). Company insiders that own Agios Pharmaceuticals stock include Celgene European Investment Co, David P Schenkein, John Duncan Higgons, Lewis Clayton Jr Cantley, Robert Nelsen and Scott Biller. View Institutional Ownership Trends for Agios Pharmaceuticals.

Who sold Agios Pharmaceuticals stock? Who is selling Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., First Trust Advisors LP, Capital International Ltd. CA, Sectoral Asset Management Inc, Point72 Asset Management L.P., Capital Guardian Trust Co., Capital International Inc. CA and Janus Henderson Group PLC. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include David P Schenkein, Lewis Clayton Jr Cantley, Robert Nelsen and Scott Biller. View Insider Buying and Selling for Agios Pharmaceuticals.

Who bought Agios Pharmaceuticals stock? Who is buying Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Alkeon Capital Management LLC, Pictet Asset Management Ltd., Crestline Management LP, Fernwood Investment Management LLC, Brown Advisory Inc., Oppenheimer & Co. Inc., Schwab Charles Investment Management Inc. and Belpointe Asset Management LLC. View Insider Buying and Selling for Agios Pharmaceuticals.

How do I buy Agios Pharmaceuticals stock?

Shares of Agios Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of Agios Pharmaceuticals stock can currently be purchased for approximately $55.00.

How big of a company is Agios Pharmaceuticals?

Agios Pharmaceuticals has a market capitalization of $2.73 billion and generates $69.89 million in revenue each year. The biopharmaceutical company earns $-198,470,000.00 in net income (profit) each year or ($6.27) on an earnings per share basis. Agios Pharmaceuticals employs 287 workers across the globe.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]


MarketBeat Community Rating for Agios Pharmaceuticals (AGIO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  230 (Vote Outperform)
Underperform Votes:  223 (Vote Underperform)
Total Votes:  453
MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Agios Pharmaceuticals (NASDAQ:AGIO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.792.792.792.77
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $73.00$73.00$71.27$63.00
Price Target Upside: 30.17% upside13.58% upside8.66% upside25.95% upside

Agios Pharmaceuticals (NASDAQ:AGIO) Consensus Price Target History

Price Target History for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017Canaccord GenuitySet Price TargetBuy$90.00HighView Rating Details
12/11/2017OppenheimerReiterated RatingBuy$83.00LowView Rating Details
12/5/2017CannReiterated RatingBuyMediumView Rating Details
11/19/2017SunTrust BanksSet Price TargetBuy$80.00N/AView Rating Details
11/2/2017Credit Suisse GroupBoost Price TargetOutperform$61.00 -> $66.00N/AView Rating Details
9/18/2017J P Morgan Chase & CoReiterated RatingBuy$76.00LowView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform -> Outperform$78.00HighView Rating Details
8/10/2017Needham & Company LLCBoost Price TargetBuy -> Buy$54.00 -> $72.00MediumView Rating Details
8/2/2017Leerink SwannUpgradeMarket Perform -> Outperform$50.00 -> $80.00HighView Rating Details
8/1/2017Janney Montgomery ScottReiterated RatingHoldHighView Rating Details
2/16/2017CowenReiterated RatingBuyN/AView Rating Details
1/17/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
8/19/2016BTIG ResearchInitiated CoverageNeutralN/AView Rating Details
8/10/2016Goldman Sachs GroupReiterated RatingNeutral$46.00N/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Agios Pharmaceuticals (NASDAQ:AGIO) Earnings History and Estimates Chart

Earnings by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ AGIO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018($1.65)N/AView Earnings Details
11/1/2017Q3 2017($1.78)($1.59)$10.85 million$11.35 millionViewN/AView Earnings Details
8/8/2017Q2 2017($1.57)($1.78)$10.68 million$11.30 millionViewListenView Earnings Details
5/4/2017Q1 2017($1.80)($1.56)$9.65 million$10.51 millionViewListenView Earnings Details
2/16/2017Q416($1.51)($1.34)$10.89 million$22.65 millionViewListenView Earnings Details
11/3/2016Q316($1.52)($1.63)$7.82 million$8.98 millionViewListenView Earnings Details
8/4/2016Q216($0.48)($1.47)$39.62 million$6.98 millionViewListenView Earnings Details
5/5/2016Q116($0.79)($0.61)$20.94 million$31.30 millionViewListenView Earnings Details
2/18/2016Q415($0.27)($1.08)$28.78 million$6.22 millionViewListenView Earnings Details
11/5/2015Q315($0.89)($1.07)$17.21 million$5.80 millionViewListenView Earnings Details
8/6/2015Q215($0.46)($0.85)$25.75 million$13.20 millionViewListenView Earnings Details
5/7/2015Q115($0.86)($0.13)$10.86 million$34.20 millionViewListenView Earnings Details
2/17/2015Q414($0.55)($0.76)$10.94 million$14.64 millionViewListenView Earnings Details
11/7/2014Q314($0.53)$0.10$8.45 million$33.90 millionViewListenView Earnings Details
8/7/2014Q2($0.47)($0.54)$11.00 million$8.41 millionViewListenView Earnings Details
5/8/2014Q1($0.37)($0.39)$7.19 million$8.41 millionViewListenView Earnings Details
3/6/2014Q4($0.34)($0.40)$6.19 million$6.70 millionViewListenView Earnings Details
11/7/2013($0.28)($0.47)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Agios Pharmaceuticals (NASDAQ:AGIO) Earnings Estimates

2017 EPS Consensus Estimate: ($6.91)
2018 EPS Consensus Estimate: ($7.22)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($1.86)($1.78)($1.81)
Q2 20173($1.91)($1.48)($1.73)
Q3 20173($1.99)($1.50)($1.76)
Q4 20173($1.69)($1.50)($1.61)
Q1 20181($2.06)($2.06)($2.06)
Q2 20181($2.21)($2.21)($2.21)
Q3 20181($2.37)($2.37)($2.37)
Q4 20181($0.58)($0.58)($0.58)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Agios Pharmaceuticals (NASDAQ:AGIO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Agios Pharmaceuticals (NASDAQ AGIO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.43%
Institutional Ownership Percentage: 94.38%
Insider Trades by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)
Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ AGIO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/7/2017Lewis Clayton Jr. CantleyDirectorSell3,838$59.37$227,862.06View SEC Filing  
12/1/2017David P SchenkeinCEOSell6,000$61.55$369,300.00View SEC Filing  
12/1/2017Scott BillerInsiderSell2,146$60.79$130,455.34View SEC Filing  
11/14/2017Lewis Clayton Jr. CantleyDirectorSell4,000$60.88$243,520.00View SEC Filing  
11/1/2017David P SchenkeinCEOSell6,000$63.85$383,100.00View SEC Filing  
11/1/2017Scott BillerInsiderSell2,146$62.69$134,532.74View SEC Filing  
10/17/2017Lewis Clayton Jr. CantleyDirectorSell4,000$71.10$284,400.00View SEC Filing  
10/16/2017Lewis Clayton Jr. CantleyDirectorSell1,000$71.09$71,090.00View SEC Filing  
10/4/2017David P SchenkeinCEOSell80,000$70.14$5,611,200.00View SEC Filing  
10/4/2017Scott BillerInsiderSell10,470$70.00$732,900.00View SEC Filing  
10/2/2017David P SchenkeinCEOSell6,000$66.76$400,560.00View SEC Filing  
10/2/2017Scott BillerInsiderSell2,146$67.23$144,275.58View SEC Filing  
9/18/2017David P SchenkeinCEOSell35,000$67.12$2,349,200.00View SEC Filing  
9/14/2017Lewis Clayton Jr. CantleyDirectorSell4,000$65.59$262,360.00View SEC Filing  
9/13/2017Lewis Clayton Jr. CantleyDirectorSell1,000$65.47$65,470.00View SEC Filing  
9/11/2017Scott BillerInsiderSell15,000$65.00$975,000.00View SEC Filing  
9/1/2017David P SchenkeinCEOSell6,000$62.20$373,200.00View SEC Filing  
9/1/2017Scott BillerInsiderSell2,146$61.99$133,030.54View SEC Filing  
8/23/2017Lewis Clayton Jr. CantleyDirectorSell4,000$56.85$227,400.00View SEC Filing  
8/2/2017David P SchenkeinCEOSell27,000$59.95$1,618,650.00View SEC Filing  
8/2/2017Scott BillerInsiderSell23,146$59.60$1,379,501.60View SEC Filing  
7/20/2017Lewis Clayton Jr. CantleyDirectorSell9,000$56.36$507,240.00View SEC Filing  
7/19/2017Lewis Clayton Jr. CantleyDirectorSell3,500$56.14$196,490.00View SEC Filing  
7/7/2017Scott BillerInsiderSell2,146$55.00$118,030.00View SEC Filing  
7/3/2017David P SchenkeinCEOSell3,000$51.18$153,540.00View SEC Filing  
6/21/2017Scott BillerInsiderSell4,292$55.00$236,060.00View SEC Filing  
6/14/2017Lewis Clayton Jr. CantleyDirectorSell2,000$50.87$101,740.00View SEC Filing  
6/7/2017David P SchenkeinCEOSell3,000$50.02$150,060.00View SEC Filing  
5/25/2017Lewis Clayton Jr. CantleyDirectorSell2,036$47.10$95,895.60View SEC Filing  
5/1/2017David P SchenkeinCEOSell3,000$50.06$150,180.00View SEC Filing  
4/24/2017Celgene European Investment CoMajor ShareholderBuy624,575$49.50$30,916,462.50View SEC Filing  
4/18/2017Lewis Clayton Jr. CantleyDirectorSell5,090$54.37$276,743.30View SEC Filing  
4/17/2017Lewis Clayton Jr. CantleyDirectorSell2,036$55.24$112,468.64View SEC Filing  
4/3/2017David P SchenkeinCEOSell3,000$58.62$175,860.00View SEC Filing  
4/3/2017Scott BillerInsiderSell2,146$58.03$124,532.38View SEC Filing  
3/23/2017Lewis Clayton Jr. CantleyDirectorSell2,036$53.11$108,131.96View SEC Filing  
3/20/2017Scott BillerInsiderSell6,438$55.00$354,090.00View SEC Filing  
3/6/2017Robert NelsenDirectorSell40,599$50.84$2,064,053.16View SEC Filing  
2/28/2017Robert NelsenDirectorSell243,082$49.36$11,998,527.52View SEC Filing  
2/23/2017Robert NelsenDirectorSell135,364$49.37$6,682,920.68View SEC Filing  
2/16/2017David P SchenkeinCEOSell6,000$50.01$300,060.00View SEC Filing  
10/27/2016Lewis Clayton Jr. CantleyDirectorSell2,504$48.94$122,545.76View SEC Filing  
10/5/2016Scott BillerInsiderSell5,000$55.00$275,000.00View SEC Filing  
9/28/2016Lewis Clayton Jr. CantleyDirectorSell627$54.00$33,858.00View SEC Filing  
9/27/2016Lewis Clayton Jr. CantleyDirectorSell627$54.15$33,952.05View SEC Filing  
9/20/2016Scott BillerInsiderSell5,000$50.00$250,000.00View SEC Filing  
8/30/2016Lewis Clayton Jr. CantleyDirectorSell627$36.81$23,079.87View SEC Filing  
8/29/2016Lewis Clayton Jr. CantleyDirectorSell627$37.81$23,706.87View SEC Filing  
7/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.80$107,171.20View SEC Filing  
7/25/2016Lewis Clayton Jr. CantleyDirectorSell627$41.85$26,239.95View SEC Filing  
6/28/2016Lewis Clayton Jr. CantleyDirectorSell2,504$41.88$104,867.52View SEC Filing  
6/27/2016Lewis Clayton Jr. CantleyDirectorSell627$40.37$25,311.99View SEC Filing  
6/8/2016Scott BillerInsiderSell27,500$65.00$1,787,500.00View SEC Filing  
5/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$51.69$129,431.76View SEC Filing  
4/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$53.44$133,813.76View SEC Filing  
4/25/2016Lewis Clayton Jr. CantleyDirectorSell627$55.00$34,485.00View SEC Filing  
3/30/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.19$93,123.76View SEC Filing  
2/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.90$94,901.60View SEC Filing  
1/29/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.93$107,496.72View SEC Filing  
12/29/2015Lewis Clayton Jr. CantleyDirectorSell10,664$64.93$692,413.52View SEC Filing  
12/15/2015John Duncan HiggonsCOOSell20,000$50.09$1,001,800.00View SEC Filing  
11/17/2015Lewis Clayton Jr. CantleyDirectorSell9,408$59.83$562,880.64View SEC Filing  
11/16/2015John Duncan HiggonsCOOSell20,000$61.51$1,230,200.00View SEC Filing  
11/2/2015Scott BillerinsiderSell5,500$77.12$424,160.00View SEC Filing  
10/23/2015Lewis Clayton Jr. CantleyDirectorSell9,704$61.16$593,496.64View SEC Filing  
10/15/2015John Duncan HiggonsCOOSell20,000$71.04$1,420,800.00View SEC Filing  
9/30/2015Scott BillerinsiderSell5,500$70.44$387,420.00View SEC Filing  
9/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$83.25$807,858.00View SEC Filing  
9/24/2015Glenn GoddardSVPSell6,000$85.97$515,820.00View SEC Filing  
9/15/2015John Duncan HiggonsCOOSell20,000$91.11$1,822,200.00View SEC Filing  
8/18/2015Lewis Clayton Jr. CantleyDirectorSell9,704$94.94$921,297.76View SEC Filing  
8/17/2015John Duncan HiggonsCOOSell20,000$92.24$1,844,800.00View SEC Filing  
7/23/2015Glenn GoddardSVPSell7,000$120.45$843,150.00View SEC Filing  
7/20/2015Scott BillerInsiderSell5,500$113.87$626,285.00View SEC Filing  
7/17/2015Glenn GoddardSVPSell13,000$113.71$1,478,230.00View SEC Filing  
7/16/2015John Duncan HiggonsCOOSell20,000$114.02$2,280,400.00View SEC Filing  
7/16/2015Lewis Clayton Jr. CantleyDirectorSell9,704$114.28$1,108,973.12View SEC Filing  
6/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.13$1,020,181.52View SEC Filing  
6/15/2015John Duncan HiggonsCOOSell7,000$105.23$736,610.00View SEC Filing  
6/8/2015Scott BillerInsiderSell5,500$121.85$670,175.00View SEC Filing  
6/1/2015Christopher BowdenInsiderSell5,000$120.67$603,350.00View SEC Filing  
6/1/2015David P SchenkeinCEOSell13,000$120.67$1,568,710.00View SEC Filing  
5/27/2015David P SchenkeinCEOSell8,929$120.05$1,071,926.45View SEC Filing  
5/27/2015Glenn GoddardSVPSell2,171$120.05$260,628.55View SEC Filing  
5/20/2015Lewis Clayton Jr. CantleyDirectorSell9,704$116.64$1,131,874.56View SEC Filing  
5/15/2015John Duncan HiggonsCOOSell7,417$112.89$837,305.13View SEC Filing  
5/12/2015David P SchenkeinCEOSell5,200$110.02$572,104.00View SEC Filing  
5/8/2015David P SchenkeinCEOSell3,900$101.32$395,148.00View SEC Filing  
5/7/2015Scott BillerInsiderSell5,500$96.32$529,760.00View SEC Filing  
4/24/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.15$1,020,375.60View SEC Filing  
4/15/2015John Duncan HiggonsCOOSell6,583$99.54$655,271.82View SEC Filing  
4/13/2015David P SchenkeinCEOSell3,900$100.03$390,117.00View SEC Filing  
4/8/2015Scott BillerInsiderSell5,500$97.64$537,020.00View SEC Filing  
4/1/2015David P SchenkeinCEOSell3,900$92.54$360,906.00View SEC Filing  
3/27/2015Lewis Clayton Jr. CantleyDirectorSell9,704$93.58$908,100.32View SEC Filing  
3/16/2015Glenn GoddardSVPSell10,000$106.24$1,062,400.00View SEC Filing  
3/16/2015John Duncan HiggonsCOOSell7,000$106.24$743,680.00View SEC Filing  
3/16/2015Scott BillerInsiderSell5,500$106.81$587,455.00View SEC Filing  
3/2/2015David P SchenkeinCEOSell7,800$107.05$834,990.00View SEC Filing  
2/13/2015David P SchenkeinCEOSell1,471$120.22$176,843.62View SEC Filing  
2/13/2015Glenn GoddardSVPSell1,316$120.31$158,327.96View SEC Filing  
2/11/2015Glenn GoddardSVPSell16,513$107.12$1,768,872.56View SEC Filing  
2/9/2015Glenn GoddardSVPSell15,000$105.81$1,587,150.00View SEC Filing  
2/2/2015David P SchenkeinCEOSell10,400$114.31$1,188,824.00View SEC Filing  
1/2/2015David P SchenkeinCEOSell13,000$110.08$1,431,040.00View SEC Filing  
1/2/2015John Duncan HiggonsCOOSell12,000$110.08$1,320,960.00View SEC Filing  
1/2/2015Scott BillerInsiderSell4,500$110.08$495,360.00View SEC Filing  
12/16/2014Celgene European Investment CoMajor ShareholderBuy228,645$110.75$25,322,433.75View SEC Filing  
12/16/2014John MaraganoreDirectorBuy1,806$110.75$200,014.50View SEC Filing  
12/1/2014David P SchenkeinCEOSell13,000$97.03$1,261,390.00View SEC Filing  
12/1/2014John Duncan HiggonsCOOSell12,000$97.03$1,164,360.00View SEC Filing  
12/1/2014Scott BillerInsiderSell4,500$97.03$436,635.00View SEC Filing  
11/3/2014Glenn GoddardSVPSell2,000$81.71$163,420.00View SEC Filing  
11/3/2014John Duncan HiggonsCOOSell13,000$81.71$1,062,230.00View SEC Filing  
11/3/2014Scott BillerInsiderSell4,500$81.71$367,695.00View SEC Filing  
10/1/2014Glenn GoddardSVPSell1,500$60.07$90,105.00View SEC Filing  
10/1/2014John Duncan HiggonsCOOSell13,000$60.07$780,910.00View SEC Filing  
10/1/2014Scott BillerInsiderSell4,500$60.07$270,315.00View SEC Filing  
9/26/2014David P SchenkeinCEOSell60,000$62.68$3,760,800.00View SEC Filing  
9/26/2014Glenn GoddardSVPSell17,500$56.53$989,275.00View SEC Filing  
9/19/2014Scott BillerInsiderSell37,996$50.45$1,916,898.20View SEC Filing  
9/2/2014Glenn GoddardSVPSell10,000$46.30$463,000.00View SEC Filing  
9/2/2014John Duncan HiggonsCOOSell13,000$46.30$601,900.00View SEC Filing  
9/2/2014Scott BillerInsiderSell4,500$46.30$208,350.00View SEC Filing  
8/26/2014John Duncan HiggonsCOOSell5,000$45.05$225,250.00View SEC Filing  
8/11/2014David P SchenkeinCEOSell4,530$40.17$181,970.10View SEC Filing  
7/1/2014David P SchenkeinCEOSell13,000$46.52$604,760.00View SEC Filing  
7/1/2014Glenn GoddardSVPSell3,500$46.52$162,820.00View SEC Filing  
7/1/2014John Duncan HiggonsCOOSell12,000$46.52$558,240.00View SEC Filing  
7/1/2014Scott BillerInsiderSell4,500$46.52$209,340.00View SEC Filing  
6/23/2014John MaraganoreDirectorBuy2,300$43.98$101,154.00View SEC Filing  
6/20/2014Scott BillerInsiderSell2,004$50.05$100,300.20View SEC Filing  
6/13/2014John Duncan HiggonsCOOSell5,000$45.27$226,350.00View SEC Filing  
6/3/2014John Duncan HiggonsCOOSell7,000$34.47$241,290.00View SEC Filing  
5/6/2014John Duncan HiggonsCOOSell5,000$45.73$228,650.00View SEC Filing  
5/1/2014Glenn GoddardSVPSell2,000$42.39$84,780.00View SEC Filing  
5/1/2014John Duncan HiggonsCOOSell7,000$42.39$296,730.00View SEC Filing  
5/1/2014Scott BillerInsiderSell4,500$42.39$190,755.00View SEC Filing  
4/29/2014Celgene European Investment Comajor shareholderBuy294,800$44.00$12,971,200.00View SEC Filing  
4/29/2014John MaraganoreDirectorBuy2,250$44.00$99,000.00View SEC Filing  
4/7/2014Glenn GoddardSVPSell2,000$45.17$90,340.00View SEC Filing  
4/7/2014John Duncan HiggonsCOOSell3,000$45.17$135,510.00View SEC Filing  
4/1/2014Glenn GoddardSVPSell4,000$38.08$152,320.00View SEC Filing  
4/1/2014John Duncan HiggonsCOOSell12,000$38.08$456,960.00View SEC Filing  
4/1/2014Scott BillerInsiderSell4,500$38.08$171,360.00View SEC Filing  
3/7/2014Glenn GoddardSVPSell17,468$42.11$735,577.48View SEC Filing  
3/7/2014John Duncan HiggonsCOOSell14,646$41.41$606,490.86View SEC Filing  
3/3/2014John Duncan HiggonsCOOSell8,000$29.85$238,800.00View SEC Filing  
3/3/2014Scott BillerInsiderSell6,000$29.85$179,100.00View SEC Filing  
2/10/2014Glenn GoddardSVPSell6,000$30.44$182,640.00View SEC Filing  
1/27/2014Glenn GoddardSVPSell7,000$26.29$184,030.00View SEC Filing  
1/21/2014Glenn GoddardSVPSell10,000$34.71$347,100.00View SEC Filing  
7/29/2013Celgene European Investment CoMajor ShareholderBuy708,333$18.00$12,749,994.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Agios Pharmaceuticals (NASDAQ AGIO) News Headlines

Source:
DateHeadline
Agios Pharmaceuticals: Updates To Thesis And A Look Toward 2018 - Seeking AlphaAgios Pharmaceuticals: Updates To Thesis And A Look Toward 2018 - Seeking Alpha
seekingalpha.com - December 14 at 3:23 PM
Agios Pharmaceuticals (AGIO) Stock Rating Reaffirmed by Canaccord GenuityAgios Pharmaceuticals (AGIO) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - December 12 at 8:38 PM
BRIEF-Agios Pharmaceuticals Presents New Safety Data From Study on Leukemia DrugBRIEF-Agios Pharmaceuticals Presents New Safety Data From Study on Leukemia Drug
www.reuters.com - December 12 at 3:22 PM
New Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial Demonstrate Durable Responses in Patients with IDH1m Relapsed or Refractory AMLNew Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial Demonstrate Durable Responses in Patients with IDH1m Relapsed or Refractory AML
finance.yahoo.com - December 12 at 3:22 PM
Agios Pharmas ivosidenib shows positive effect in early-stage AML study; shares ahead 3% after hours - Seeking AlphaAgios Pharma's ivosidenib shows positive effect in early-stage AML study; shares ahead 3% after hours - Seeking Alpha
seekingalpha.com - December 12 at 7:39 AM
Data from Phase 1 Studies of Ivosidenib or Enasidenib in Combination with Full Doses of Standard of Care Chemotherapy Demonstrate Tolerability and Preliminary Clinical Activity in Newly Diagnosed AML Patients With an IDH MutationData from Phase 1 Studies of Ivosidenib or Enasidenib in Combination with Full Doses of Standard of Care Chemotherapy Demonstrate Tolerability and Preliminary Clinical Activity in Newly Diagnosed AML Patients With an IDH Mutation
finance.yahoo.com - December 12 at 7:39 AM
Agios targeting cancer medicinesAgios targeting cancer medicines
finance.yahoo.com - December 12 at 7:39 AM
Agios Pharmaceuticals (AGIO) Buy Rating Reiterated at OppenheimerAgios Pharmaceuticals' (AGIO) Buy Rating Reiterated at Oppenheimer
www.americanbankingnews.com - December 11 at 5:08 PM
Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically ... - GlobeNewswire (press release)Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically ... - GlobeNewswire (press release)
globenewswire.com - December 11 at 7:22 AM
Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase DeficiencyAgios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency
finance.yahoo.com - December 11 at 7:22 AM
Cambridge biotechs among big winners at ASH blood disease conferenceCambridge biotechs among big winners at ASH blood disease conference
finance.yahoo.com - December 11 at 7:22 AM
Agios Pharmaceuticals, Inc. (AGIO) Director Sells $227,862.06 in StockAgios Pharmaceuticals, Inc. (AGIO) Director Sells $227,862.06 in Stock
www.americanbankingnews.com - December 8 at 5:50 PM
Agios Pharmaceuticals, Inc. (AGIO) Insider Sells $130,455.34 in StockAgios Pharmaceuticals, Inc. (AGIO) Insider Sells $130,455.34 in Stock
www.americanbankingnews.com - December 5 at 7:12 PM
Insider Selling: Agios Pharmaceuticals, Inc. (AGIO) CEO Sells 6,000 Shares of StockInsider Selling: Agios Pharmaceuticals, Inc. (AGIO) CEO Sells 6,000 Shares of Stock
www.americanbankingnews.com - December 5 at 6:20 PM
Agios Pharma (AGIO) Names Jacqualyn Fouse Ph.D. to BoardAgios Pharma (AGIO) Names Jacqualyn Fouse Ph.D. to Board
www.streetinsider.com - December 5 at 3:23 PM
IBD Rating Upgrades: Agios Pharmaceuticals Flashes Improved Relative Price StrengthIBD Rating Upgrades: Agios Pharmaceuticals Flashes Improved Relative Price Strength
finance.yahoo.com - December 5 at 3:23 PM
Cann Reaffirms Buy Rating for Agios Pharmaceuticals (AGIO)Cann Reaffirms Buy Rating for Agios Pharmaceuticals (AGIO)
www.americanbankingnews.com - December 5 at 11:22 AM
Agios Pharma (AGIO) Names Jacqualyn Fouse Ph.D. to Board - StreetInsider.comAgios Pharma (AGIO) Names Jacqualyn Fouse Ph.D. to Board - StreetInsider.com
www.streetinsider.com - December 5 at 7:35 AM
ASH: Heres Why You Need To Keep An Eye On ARGX, MGNX, KURA, AGIOASH: Here's Why You Need To Keep An Eye On ARGX, MGNX, KURA, AGIO
www.rttnews.com - December 4 at 3:22 PM
ASH: Heres Why You Need To Keep An Eye On ARGX, MGNX, KURA, AGIO - NasdaqASH: Here's Why You Need To Keep An Eye On ARGX, MGNX, KURA, AGIO - Nasdaq
www.nasdaq.com - December 4 at 7:40 AM
Critical Contrast: Agios Pharmaceuticals (AGIO) & Its CompetitorsCritical Contrast: Agios Pharmaceuticals (AGIO) & Its Competitors
www.americanbankingnews.com - December 3 at 11:42 AM
Agios Pharmaceuticals, Inc. (AGIO) Expected to Announce Quarterly Sales of $16.14 MillionAgios Pharmaceuticals, Inc. (AGIO) Expected to Announce Quarterly Sales of $16.14 Million
www.americanbankingnews.com - November 28 at 8:28 AM
ETFs with exposure to Agios Pharmaceuticals, Inc. : November 27, 2017ETFs with exposure to Agios Pharmaceuticals, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 3:18 PM
[$$] VC Focus: Once Rare, Health-Care Megarounds Grow More Common[$$] VC Focus: Once Rare, Health-Care Megarounds Grow More Common
finance.yahoo.com - November 27 at 9:19 AM
Agios Pharmaceuticals, Inc. (AGIO) Given Average Rating of "Buy" by AnalystsAgios Pharmaceuticals, Inc. (AGIO) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - November 26 at 11:44 AM
Fighting Cancer One Patient At A TimeFighting Cancer One Patient At A Time
finance.yahoo.com - November 21 at 4:11 PM
Agios Posts New Data on Glioma Candidate from Dose Expansion - NasdaqAgios Posts New Data on Glioma Candidate from Dose Expansion - Nasdaq
www.nasdaq.com - November 20 at 10:07 PM
Biotech Stock Performance Review -- Achillion Pharma, Aduro BioTech, Agios ...Biotech Stock Performance Review -- Achillion Pharma, Aduro BioTech, Agios ...
www.prnewswire.com - November 20 at 5:06 PM
Agios Pharmaceuticals Enters Oversold Territory (AGIO)Agios Pharmaceuticals Enters Oversold Territory (AGIO)
www.nasdaq.com - November 20 at 5:06 PM
Agios Pharmaceuticals, Inc. (AGIO) PT Set at $80.00 by SunTrust Banks, Inc.Agios Pharmaceuticals, Inc. (AGIO) PT Set at $80.00 by SunTrust Banks, Inc.
www.americanbankingnews.com - November 20 at 8:18 AM
Agios Pharma (AGIO) Reports Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) - StreetInsider.comAgios Pharma (AGIO) Reports Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) - StreetInsider.com
www.streetinsider.com - November 19 at 3:36 PM
Agios Pharmas ivosidenib shows treatment effect in early-stage glioma study; shares ahead 3% premarket - Seeking AlphaAgios Pharma's ivosidenib shows treatment effect in early-stage glioma study; shares ahead 3% premarket - Seeking Alpha
seekingalpha.com - November 18 at 5:44 AM
Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 ... - GlobeNewswire (press release)Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 ... - GlobeNewswire (press release)
globenewswire.com - November 18 at 5:44 AM
Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive GliomaAgios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive Glioma
finance.yahoo.com - November 18 at 5:44 AM
Agios Pharmaceuticals, Inc. (AGIO) Given a $83.00 Price Target by Oppenheimer Holdings, Inc. AnalystsAgios Pharmaceuticals, Inc. (AGIO) Given a $83.00 Price Target by Oppenheimer Holdings, Inc. Analysts
www.americanbankingnews.com - November 17 at 12:22 PM
ETFs with exposure to Agios Pharmaceuticals, Inc. : November 16, 2017ETFs with exposure to Agios Pharmaceuticals, Inc. : November 16, 2017
finance.yahoo.com - November 16 at 3:47 PM
Lewis Clayton Jr. Cantley Sells 4,000 Shares of Agios Pharmaceuticals, Inc. (AGIO) StockLewis Clayton Jr. Cantley Sells 4,000 Shares of Agios Pharmaceuticals, Inc. (AGIO) Stock
www.americanbankingnews.com - November 15 at 8:44 PM
Investors Purchase High Volume of Agios Pharmaceuticals Put Options (AGIO)Investors Purchase High Volume of Agios Pharmaceuticals Put Options (AGIO)
www.americanbankingnews.com - November 12 at 4:04 AM
 Brokerages Expect Agios Pharmaceuticals, Inc. (AGIO) Will Post Quarterly Sales of $16.14 Million Brokerages Expect Agios Pharmaceuticals, Inc. (AGIO) Will Post Quarterly Sales of $16.14 Million
www.americanbankingnews.com - November 10 at 11:03 AM
Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : November 9, 2017Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : November 9, 2017
finance.yahoo.com - November 9 at 4:34 PM
 Analysts Expect Agios Pharmaceuticals, Inc. (AGIO) Will Post Earnings of -$1.69 Per Share Analysts Expect Agios Pharmaceuticals, Inc. (AGIO) Will Post Earnings of -$1.69 Per Share
www.americanbankingnews.com - November 8 at 3:08 AM
ETFs with exposure to Agios Pharmaceuticals, Inc. : November 6, 2017ETFs with exposure to Agios Pharmaceuticals, Inc. : November 6, 2017
finance.yahoo.com - November 6 at 4:20 PM
Analysts Set Expectations for Agios Pharmaceuticals, Inc.s FY2017 Earnings (AGIO)Analysts Set Expectations for Agios Pharmaceuticals, Inc.'s FY2017 Earnings (AGIO)
www.americanbankingnews.com - November 6 at 8:06 AM
Oppenheimer Holdings Comments on Agios Pharmaceuticals, Inc.s FY2017 Earnings (AGIO)Oppenheimer Holdings Comments on Agios Pharmaceuticals, Inc.'s FY2017 Earnings (AGIO)
www.americanbankingnews.com - November 6 at 8:06 AM
Brokers Offer Predictions for Agios Pharmaceuticals, Inc.s FY2017 Earnings (AGIO)Brokers Offer Predictions for Agios Pharmaceuticals, Inc.'s FY2017 Earnings (AGIO)
www.americanbankingnews.com - November 6 at 8:06 AM
Agios Pharmaceuticals, Inc. (AGIO) Insider Scott Biller Sells 2,146 SharesAgios Pharmaceuticals, Inc. (AGIO) Insider Scott Biller Sells 2,146 Shares
www.americanbankingnews.com - November 3 at 6:30 PM
Agios Pharmaceuticals, Inc. (AGIO) CEO Sells $383,100.00 in StockAgios Pharmaceuticals, Inc. (AGIO) CEO Sells $383,100.00 in Stock
www.americanbankingnews.com - November 3 at 5:42 PM
Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 3:32 PM
Todays Research Reports on Stocks to Watch: Exelixis, Inc. and Agios PharmaceuticalsToday's Research Reports on Stocks to Watch: Exelixis, Inc. and Agios Pharmaceuticals
finance.yahoo.com - November 3 at 9:55 AM
Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y - NasdaqAgios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y - Nasdaq
www.nasdaq.com - November 2 at 3:53 PM

SEC Filings

Agios Pharmaceuticals (NASDAQ:AGIO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Agios Pharmaceuticals (NASDAQ:AGIO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Agios Pharmaceuticals (NASDAQ AGIO) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.